Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 6/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2-Dichlorobenzene SCHEMBL27913434 | 0.84 | HTR2C (0.39) | CTSKCTSLCTSBCTSSHTR2C | |
| SCHEMBL1446179 | 0.83 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CTSKCTSD | |
| SCHEMBL2754735 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSKCTSD | |
| SCHEMBL4693101 | 0.81 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CTSKCTSD | |
| SCHEMBL111602 | 0.81 | CA14 (0.40) | HDAC6HDAC1HDAC2CTSKCTSD | |
| SCHEMBL30315135 | 0.80 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL30536132 | 0.80 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL28089582 | 0.80 | HDAC6 (0.42) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL1328517 | 0.80 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSKCTSD | |
| SCHEMBL380577 | 0.80 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CTSKCA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300942-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2021-09-30 | — | — | US | claimed |
| EP-3539967-A1 | PROCESS FOR THE PREPARATION OF FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS | Sunovion Pharmaceuticals Inc. (US) | 2019-09-18 | — | — | EP | claimed |
| US-20180057506-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-03-01 | — | — | US | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-5041454-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
| US-4975439-A | Gastrointestinal motility stimulating properties | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-12-04 | — | — | US | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0309043-A2 | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-03-29 | — | — | EP | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | HDAC6 896/4885HDAC1 697/4885HDAC2 724/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HDAC6 1262/4885HDAC1 447/4885HDAC2 1705/4885 |
| US-20210300942-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | GRIN2C, GRIN2A, ATP6V1B2 | HDAC6 395/4885HDAC1 194/4885HDAC2 452/4885 |
| US-20180057506-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | GRIN2C, GRIN2A, ATP6V1B2 | HDAC6 395/4885HDAC1 194/4885HDAC2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.